TrialThe European respiratory journal2025

A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.

Dave Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.